Evidence map›Paper›PMID 42897340›Full record

ArticleCancer medicine2026

Survival Outcomes in Chronic Lymphocytic Leukemia During the Novel Agent Era: A Population-Based Analysis.

Mengyang Di, Scott F Huntington, Jenna M Voutsinas, Vicky Q Wu, Chaitra S Ujjani, Scott D Ramsey, Jennifer J Huang, Ajay K Gopal, Mazyar Shadman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mengyang DiDivision of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-6165-2617
Scott F HuntingtonSection of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0001-7071-6475
Jenna M VoutsinasStatistics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Vicky Q WuStatistics Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Chaitra S UjjaniDivision of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Scott D RamseyFred Hutchinson Cancer Center, Hutchinson Institute for Cancer Outcomes Research, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5972-8280
Jennifer J HuangDivision of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-0863-9389
Ajay K GopalDivision of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-3023-6834
Mazyar ShadmanDivision of Hematology-Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoimmunotherapy (CIT) had long been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) until 2014 when the first novel agent, ibrutinib, was approved in the United States. Numerous novel therapies have since become available. Nevertheless, as novel therapies have largely replaced CIT in CLL/SLL, its impact on survival has yet to be examined on the population level. In this study, we used the SEER (Surveillance, Epidemiology, and End Results) database to compare survival in patients with CLL/SLL before and after the approval of the first novel therapy. We included 9913 patients who started treatment within 2 years of CLL/SLL diagnosis. In the multivariable analyses, the overall survival improved significantly (hazard ratio [HR]: 0.86, 95% confidence interval: 0.81, 0.92), and death from CLL/SLL and other cancer (subdistribution-HR: 0.69 and 0.77) also decreased significantly. Nevertheless, CLL/SLL remains the main cause of death during the novel agent era.

Indexed as

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellAgedAged, 80 and overFemaleHumansMaleMiddle AgedPiperidinesSEER ProgramTreatment OutcomeUnited StatesAntineoplastic AgentsPiperidinescause of deathchronic lymphocytic leukemia/small lymphocytic lymphomanovel agentsoverall survival

Identifiers

PMID42897340
PMCPMC13680548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.